Hiding in Plain Sight: Finding the NASH Patient

Finding NASH patients for clinical trials can be a major challenge.  Acurian has a best-in-class capability to help you find more NASH patients, faster. With a proprietary database of 120 million households, including thousands of confirmed NAFLD patients, plus state-of-the-art, noninvasive screening, we are able to deliver high quality patients who meet your stringent criteria, with fixed budget models.

Acurian Quickly Closes a Critical Enrollment Gap for an IBS Study

This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.

With Acurian’s Help, a Crucial Crohn’s Disease Study Completes Enrollment 60% Faster

This mid-sized biopharmaceutical company’s growth strategy relies on the development of novel immunotherapy agents. One of its biologics carried the potential to treat a range of autoimmune diseases, including Crohn’s disease or CD. The sponsor believed this agent could fill a substantial, unmet need for CD patients: more effective maintenance therapies that are also safe for long-term use.


We make gastroenterology trials less painful…and easier to digest.

Our success is a combination of aligning the enrollment process with today’s realities, customized solutions, and true insight into site relationships. From OIC/OIBD, IBS and GERD, to Crohn’s disease, Acurian makes trials a lot less trying.

Acurian is the leader in the patient recruitment and retention industry.

Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.